# GSK Acquires Nuvalent for $10.6 Billion in Its Largest Deal in Over a Decade

> ma · REPORTED · 2026-06-01

In June 2026, GSK agreed to acquire oncology biotech Nuvalent for $10.6 billion in an all-cash deal at $124 per share, a 40% premium, securing two late-stage potential best-in-class lung cancer inhibitors zidesamtinib and neladalkib targeting ROS1 and ALK mutations, both under FDA review with decisions expected in late 2026.

- Company: GSK / Nuvalent
- Sector: oncology
- Primary source: https://ibinterviewquestions.com/guides/healthcare-investment-banking/healthcare-mega-deals-2024-2026

---
Source: MedFuel Intel news monitor. Verification tier: REPORTED. Informational only, not investment advice. Corrections: media@medfuelinc.com.